Session Chair Profile
Dr. Baras serves as Vice President and Head of the Regeneron Genetics Center (RGC), one of the largest human genetics programs in the world, spanning large-scale sequencing, informatics, and translational sciences using human genetics to advance and guide the development of Regeneron’s pipeline of important new medicines. He has established and leads several foundational genomics collaborations, such as with the Geisinger Health System to sequence at least 250,000 participants and with the UK Biobank to sequence 500,000 participants. The RGC has produced many high impact discoveries identifying new drug targets, validating existing development programs, and contributing important new gene discoveries. The RGC has sequenced more than 250,000 individuals to date, collaborating with more than 50 institutions around the world. Previously, Dr. Baras held roles and responsibilities at Regeneron across R&D and business development. Prior to Regeneron, Dr. Baras contributed to other biotechnology ventures and conducted research spanning antibody based therapeutics, cancer research, and nanotechnology applications in drug development. Dr. Baras received his Bachelor’s of Science, M.D., and M.B.A., all from Duke University.
Session Abstract – PMWC 2018 Silicon Valley
Session Synopsis: Building robust databases via which to analyze genomic data and making meaningful associations between genes and diseases will ultimately lead to new drug targets and the ability to help guide the development of new therapeutics. The different presenters in this session will illustrate various ways of new drug design that are based on recent technological advancements and genetic insights.